每经头条（nbdtoutiao）——688496，被证监会立案！刚上市业绩就变脸，亏损超1亿元；核心产品受重 创：第一大客户"自产自用"，减少采购 每经AI快讯，华润双鹤（SH 600062，收盘价：18.68元）11月25日晚间发布公告称，近日，华润双鹤药 业股份有限公司全资子公司华润赛科药业有限责任公司收到了国家药品监督管理局颁发的比索洛尔氨氯 地平片《药品注册证书》。产品名称为"比索洛尔氨氯地平片"。 （记者 贾运可） 2025年1至6月份，华润双鹤的营业收入构成为：非输液占比75.13%，输液占比25.98%，分部间抵销占 比-1.11%。 截至发稿，华润双鹤市值为194亿元。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－099 华润双鹤药业股份有限公司 关于全资子公司华润赛科药业有限责任公司 比索洛尔氨氯地平片获得药品注册证书的公告 三、同类药品的市场状况 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 华润赛科药业有限责任公司(以下简称"华润赛科")收到了国家药品监 督管理局(以下简称"国家药监局")颁发的比索洛尔氨氯地平片(以下 简称"该药品")《药品注册证书》。现将相关情况公告如下： | 一、药品注册证书主要内容 | | --- | | | 药品通用名称：比索洛尔氨氯地平片 | | --- | --- | | 药品名称 | 英 文 名 拉 丁 名 ： / Bisoprolol Fumarate and | | | Amlodipine Besilate Tablets | | 剂型 | 片剂 | | 注册分类 | 化学药品 4 类 | | 规格 | 富马酸比索洛尔 5mg 与苯磺酸氨氯地平(按 | | | ...

智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司华润赛科药业有限责任公司 (简称"华润赛科")收到了国家药品监督管理局颁发的比索洛尔氨氯地平片《药品注册证书》。 比索洛尔氨氯地平片作为高血压治疗的替代疗法，用于目前同时服用与复方制剂剂量相同的单药且血压 控制良好的患者。 ...

Core Insights - The recent announcement of the "Chinese Family Common Medicine Listed Brands" recognized two products from China Resources Double Crane, highlighting their quality and market reputation [1] Group 1: Brand Heritage and Product Matrix - China Resources Double Crane has over 80 years of history, integrating the mission of "caring for the public and health of the people" into its operations [2] - The company has developed a comprehensive product matrix covering key therapeutic areas such as cardiovascular, pediatrics, anti-infection, metabolism, and endocrinology [2] Group 2: Product Advantages and User Value - The winning product, Linghuang Amine Cough Tablets, is a compound cold medicine that combines traditional Chinese medicine with Western medicine, effectively alleviating symptoms of common colds and flu [4] - The other award-winning product, Jujube Seed Anshen Granules, is based on traditional Chinese medicine principles, aimed at improving sleep quality and is recommended in various clinical guidelines [5] Group 3: Commitment to Quality and Future Outlook - China Resources Double Crane emphasizes strict quality management throughout the entire process of research, production, and quality control, ensuring the safety and effectiveness of its products [6] - The company aims to continue product innovation and upgrade, aspiring to deliver more high-quality medicines to households and contribute to the "Healthy China" strategy [7]

（文章来源：证券日报） 证券日报网讯 11月24日晚间，华润双鹤发布关于公司2021年限制性股票激励计划预留授予部分第二个 解除限售期解锁暨限制性股票上市公告称，公司本次股票上市类型为股权激励股份；股票认购方式为网 下，本次股票上市流通总数为347，068股。本次股票上市流通日期为2025年11月28日。 ...

本次股票上市流通日期为2025 年 11 月 28 日。 华润双鹤药业股份有限公司(以下简称"公司")第十届董事会第十 四次会议和第十届监事会第十一次会议审议通过了《关于公司 2021 年限制性股票激励计划预留授予部分第二个解除限售期解除限售条 件成就的议案》。根据《华润双鹤药业股份有限公司 2021 年限制性股 票激励计划(2022 年 12 月修订稿)》(以下简称"激励计划")的规定及公 司 2022 年第一次临时股东大会的授权，公司董事会认为公司激励计 划规定的预留授予部分限制性股票第二个解除限售期解除限售条件 已经成就。本次可解除限售的激励对象人数为 40 人，可解除限售的 1 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-098 华润双鹤药业股份有限公司 关于公司 2021 年限制性股票激励计划预留授予部分 第二个解除限售期解锁暨限制性股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为347,068股。 ...

在医药行业转型升级的关键期，华润双鹤正以清晰的战略布局书写高质量发展答卷。华润双鹤董事长陆文超日前在接受中国证券报记者专访时表示，华润 双鹤的发展始终与国家战略、民众需求同频共振，通过深耕集采锤炼全价值链硬实力，以"处方药龙头打造+合成生物突破"双轮驱动构建核心竞争力，更 依托国际化布局拓宽发展边界，为企业长远发展注入强劲动能。 华润双鹤总部大楼 华润双鹤供图 构建全价值链硬实力 "华润双鹤的发展轨迹，始终与国家战略部署、民众健康需求紧密相连。"陆文超表示，从地方药企到全国性集团，从规模扩张到高质量发展，公司每一次 转型都紧扣时代脉搏，在顺应变革中实现可持续发展。"如今华润双鹤已构建起覆盖抗感染、慢病、专科等多个领域的产品体系，既在市场变化中保持稳 健活力，也为守护国民健康持续发力。" 国家药品集中带量采购政策的落地，成为华润双鹤锤炼核心能力的重要契机。陆文超表示，政策推出以来，公司便确立了积极拥抱的战略方向，旨在通过 深度参与集采获取政策红利。截至目前，公司累计有近60个产品在国家集采中中标，超过70%的产品在省级及联盟集采中中选。 "参与集采，是我们构建全价值链低成本能力的'牛鼻子'和核心纽带。"陆文超说 ...

Core Viewpoint - China Resources Double Crane is strategically positioning itself for high-quality development in the pharmaceutical industry by aligning with national strategies and public health needs, focusing on a dual approach of prescription drug leadership and breakthroughs in synthetic biology [1][3]. Group 1: Strategic Development - The company has established a comprehensive product system covering multiple fields such as anti-infection, chronic diseases, and specialized areas, maintaining robust vitality amid market changes [1]. - The implementation of the national drug centralized procurement policy has provided an opportunity for the company to enhance its core capabilities, with nearly 60 products winning bids in national procurement and over 70% in provincial and alliance procurements [1][2]. Group 2: Cost Control and Marketing Strategy - Participation in centralized procurement is seen as a key to building low-cost capabilities across the entire value chain, necessitating industry-leading cost control and large-scale production advantages [2]. - The company has optimized its marketing strategy by developing differentiated promotion tactics for different product types, focusing on broad coverage for key products and specialized promotion for non-procurement products [2]. Group 3: R&D and Innovation - The company has increased its R&D investment intensity from 3.7% to nearly 8%, while maintaining sustainable revenue and profit growth through a strategy of cost control, precise R&D, and model innovation [3][5]. - The company has adopted a "precise project initiation + risk control" approach to enhance R&D efficiency and has established overseas authorization evaluation standards to validate R&D quality [2][5]. Group 4: Growth Strategy - The company aims to establish itself as the "number one brand in prescription drugs" and to create a second growth curve through synthetic biology technology, with external mergers and acquisitions being a key strategy [3][4]. - Recent acquisitions, such as that of Henan Zhongshuai, exemplify the company's strategy to enhance its product pipeline and profitability while addressing unmet clinical needs [3][4]. Group 5: Internationalization - The company has developed an international network covering over 50 countries, focusing on raw material drug exports, and aims to extend its reach into formulation exports during the "14th Five-Year Plan" [6][7]. - The internationalization strategy includes establishing production bases for complex injectables and leveraging tax incentives in Hainan to create an international production base in the health sector [6][7].

Group 1 - The Artemisinin concept index rose by 0.31%, ranking 10th among concept sectors, with three stocks increasing in value, including Delong Huineng, Rundu Co., and Haizheng Pharmaceutical, which rose by 4.35%, 0.87%, and 0.19% respectively [1] - The leading decliners in the sector included Fosun Pharma, New Hecheng, and Baiyunshan, which fell by 1.23%, 0.36%, and 0.34% respectively [1] Group 2 - The main capital flow analysis indicates a net outflow of 176 million yuan from the Artemisinin concept sector, with only one stock, Delong Huineng, experiencing a net inflow of 8.0428 million yuan [2] - The capital flow rankings for the Artemisinin concept show that Delong Huineng had a trading volume of 4.35% and a turnover rate of 13.19%, while other stocks like Kunming Pharmaceutical Group and Rundu Co. had net outflows of 1.72 million yuan and 3.06 million yuan respectively [2][3]

Core Viewpoint - Recently, China Resources Double Crane (华润双鹤) announced that its subsidiary, Hunan Xiangzhong Pharmaceutical Co., Ltd., received the drug registration certificate for Oxcarbazepine tablets from the National Medical Products Administration (NMPA), which is expected to enhance the company's product line and market competitiveness [1][2]. Group 1: Drug Registration and Market Potential - The Oxcarbazepine tablets are indicated for the treatment of primary generalized tonic-clonic seizures and partial seizures in adults and children aged 5 and above [1]. - The research and development of this generic drug began in August 2021, with the application for market approval submitted in July 2024 and the approval expected in November 2025 [1]. - The global sales of Oxcarbazepine tablets are projected to reach $351 million in 2024, with the brand "Trileptal" accounting for $162 million of that total [1]. Group 2: Competitive Landscape - In the Chinese market, there are 10 approved manufacturers of Oxcarbazepine tablets, with 9 having passed or deemed to have passed the consistency evaluation [2]. - The total sales of Oxcarbazepine tablets in the domestic medical and retail markets are estimated at 738 million yuan in 2024, with Novartis holding a market share of 74.17%, followed by Beijing Four Ring Pharmaceutical at 13.78% and Wuhan Renfu Pharmaceutical at 11.85% [2]. Group 3: Company Overview and Financial Performance - China Resources Double Crane operates 24 subsidiaries and employs 13,000 staff, focusing on new drug research and development, formulation production, drug sales, and active pharmaceutical ingredient production [2]. - The company reported a third-quarter revenue of 2.542 billion yuan, a year-on-year decrease of 2.96%, while net profit increased by 6.71% to 374 million yuan [3]. - For the first three quarters of 2025, the total revenue was 8.283 billion yuan, down 3.1% year-on-year, with net profit declining by 3.4% to 1.35 billion yuan [3]. Group 4: Recent Drug Approvals - Recently, the company has received multiple drug registration certificates for its subsidiaries, including Bosentan dispersible tablets for pulmonary arterial hypertension and a new injection for acute coronary syndrome [4].